US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Evommune

14.02

+0.45003.32%

Post-market: 14.020.00000.00%19:32 EDT

Volume:326.55K

Turnover:4.57M

Market Cap:508.82M

PE:-5.37

High:14.25

Open:13.74

Low:13.70

Close:13.57

52wk High:33.20

52wk Low:10.47

Shares:36.29M

Float Shares:19.98M

Volume Ratio:0.79

T/O Rate:1.63%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.6090

EPS(LYR):-11.2228

ROE:-52.11%

ROA:-31.99%

PB:1.83

PE(LYR):-1.25

Loading ...

Overview Company News Filings

Analysts Are Bullish on Top NA Stocks: BitGo Holdings, Inc. Class A (BTGO), Evommune, Inc. (EVMN)

Evercore ISI Keeps Their Buy Rating on Evommune, Inc. (EVMN)

RBC Adjusts PT on Evommune to $29 From $30, Maintains Outperform Speculative Risk Rating

MT Newswires Live

Evommune price target lowered to $29 from $30 at RBC Capital

Analysts Conflicted on These NA Names: Fiserv (FISV), Evommune, Inc. (EVMN) and Waystar Holding Corp. (WAY)

Evommune Posts Corporate Presentation Outlining Phase 2 Inflammation-Drug Pipeline Focusing on Evo756, Evo301

Evommune Q2 FY26 Net Loss Widens to $32.25 Million

Evommune Starts Phase 2b Trial of Evo756 for Migraine Prevention

Evommune - Top-Line Data from Phase 2B Trial Expected in 2027

THOMSON REUTERS

Evommune Initiates Phase 2B Clinical Trial of Mrgprx2 Inhibitor Evo756 in Migraine Prophylaxis

THOMSON REUTERS

Evommune CFO Kyle Carver Acquires 1,000 Common Shares for $13,260

Independent Director of Evommune Arthur Kirsch Buys More Stock

Simply Wall St.

Evommune Director Arthur S. Kirsch Reports Purchase of $133,000 in Common Shares

Evommune Publishes Corporate Deck Outlining Chronic Inflammation Drug Pipeline, Led by Evo756 and Evo301 Programs

Stifel Nicolaus Sticks to Their Buy Rating for Evommune, Inc. (EVMN)

Evommune’s EVO756 Migraine Trial: What Investors Should Know About This New Phase 2 Study

Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market

Evommune is Maintained at Overweight by Morgan Stanley

HC Wainwright Downgrades Evommune to Neutral From Buy

MT Newswires Live

U.S. Research Roundup- Comcast, Honeywell Aerospace, Qualys

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/EVMN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EVMN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","market":"US","secType":"STK","nameCN":"Evommune","latestPrice":14.02,"timestamp":1787342400000,"preClose":13.57,"halted":0,"volume":326552,"hourTrading":{"tag":"盘后","latestPrice":14.02,"preClose":14.02,"latestTime":"19:32 EDT","volume":5950,"amount":83404.12,"timestamp":1787355127959,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.033161385408990364,"floatShares":19982000,"shares":36292113,"eps":-2.609,"marketStatus":"Market Closed","change":0.45,"latestTime":"08-21 16:00:00 EDT","open":13.74,"high":14.25,"low":13.7,"amount":4565526.77752,"amplitude":0.040531,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.609,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1762405200000,"exchange":"NYSE","adjPreClose":13.57,"preHourTrading":{"tag":"盘前","latestPrice":13.74,"preClose":13.57,"latestTime":"07:51 EDT","volume":1,"amount":13.74,"timestamp":1787313097952,"change":0.17,"changeRate":0.012528,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":14.02,"preClose":14.02,"latestTime":"19:32 EDT","volume":5950,"amount":83404.12,"timestamp":1787355127959,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7864220387572776,"impliedVol":1.4355,"impliedVolPercentile":0.6905},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","floatShares":19982000,"roa":"-31.99%","roe":"-52.11%","lyrEps":-11.222761,"volumeRatio":0.7864220387572776,"shares":36292113,"dividePrice":0,"high":14.25,"amplitude":0.040531,"preClose":13.57,"low":13.7,"week52Low":10.47,"pbRate":"1.83","psRate":"50.88","week52High":33.2,"institutionHeld":0,"latestPrice":14.02,"eps":-2.609,"divideRate":0,"volume":326552,"delay":0,"ttmEps":-2.609,"open":13.74,"prevYearClose":17.12,"prevWeekClose":14.65,"prevMonthClose":11.25,"prevQuarterClose":13.29,"fiveDayClose":14.65,"twentyDayClose":11.36,"sixtyDayClose":23.34},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EVMN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"EVMN","fiscalQuarterEnding":"2026/06","expectedEps":-0.68,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.89},{"market":"US","date":"2026-05-07","symbol":"EVMN","fiscalQuarterEnding":"2026/03","expectedEps":-0.83,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.64},{"market":"US","date":"2026-03-05","symbol":"EVMN","fiscalQuarterEnding":"2025/12","expectedEps":-0.82,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-1.43}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EVMN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EVMN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.5455,"hold":0.1818,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5455,"analysts":11,"updateTime":1782878400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EVMN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EVMN","date":"2026-08-21","current":-5.373706,"percent":0.994975,"low":-16.229076,"twenty":-12.450318,"median":-9.782121,"eighty":-7.430686,"high":-5.090694,"avg":-9.990083,"sd":2.778399,"marketCap":492483973},"quantilePoints":[{"date":"2025-11-07","current":-9.395174,"twenty":-7.823584,"median":-7.430686,"eighty":-7.430686,"marketCap":608469038},{"date":"2025-11-14","current":-8.461694,"twenty":-9.04686,"median":-8.505813,"eighty":-7.430686,"marketCap":548013143},{"date":"2025-11-21","current":-8.689259,"twenty":-9.04686,"median":-8.689259,"eighty":-7.430686,"marketCap":562751147},{"date":"2025-11-28","current":-9.618094,"twenty":-9.051504,"median":-8.707835,"eighty":-8.049291,"marketCap":622906267},{"date":"2025-12-05","current":-10.184684,"twenty":-9.618094,"median":-8.986487,"eighty":-8.483986,"marketCap":659600890},{"date":"2025-12-12","current":-9.657505,"twenty":-9.633858,"median":-9.000419,"eighty":-8.483986,"marketCap":592227156},{"date":"2025-12-19","current":-7.716136,"twenty":-9.618094,"median":-8.986487,"eighty":-8.244704,"marketCap":473176635},{"date":"2025-12-26","current":-9.042428,"twenty":-9.528926,"median":-9.016673,"eighty":-8.355807,"marketCap":554508795},{"date":"2026-01-02","current":-8.800817,"twenty":-9.392482,"median":-9.003431,"eighty":-8.469125,"marketCap":539692472},{"date":"2026-01-09","current":-9.37143,"twenty":-9.380689,"median":-8.972554,"eighty":-8.293747,"marketCap":574684215},{"date":"2026-01-16","current":-10.075701,"twenty":-9.649623,"median":-9.019686,"eighty":-8.354639,"marketCap":617872222},{"date":"2026-01-23","current":-9.710714,"twenty":-9.690151,"median":-9.037572,"eighty":-8.461694,"marketCap":595490116},{"date":"2026-01-30","current":-11.129537,"twenty":-9.775997,"median":-9.042428,"eighty":-8.498847,"marketCap":682496613},{"date":"2026-02-06","current":-8.564346,"twenty":-9.775997,"median":-9.064213,"eighty":-8.549933,"marketCap":525191389},{"date":"2026-02-13","current":-14.332171,"twenty":-9.885497,"median":-9.065437,"eighty":-8.563866,"marketCap":878891712},{"date":"2026-02-20","current":-14.769127,"twenty":-10.094711,"median":-9.253195,"eighty":-8.56425,"marketCap":905687191},{"date":"2026-02-27","current":-13.689588,"twenty":-10.579486,"median":-9.338016,"eighty":-8.621921,"marketCap":839486596},{"date":"2026-03-06","current":-11.484529,"twenty":-11.200535,"median":-9.381712,"eighty":-8.67867,"marketCap":790939493},{"date":"2026-03-13","current":-12.018327,"twenty":-12.245567,"median":-9.479385,"eighty":-8.689259,"marketCap":827702188},{"date":"2026-03-20","current":-12.321662,"twenty":-12.396972,"median":-9.618094,"eighty":-8.70412,"marketCap":848592844},{"date":"2026-03-27","current":-12.379191,"twenty":-12.362455,"median":-9.695292,"eighty":-8.728757,"marketCap":852554865},{"date":"2026-04-02","current":-11.725452,"twenty":-12.336306,"median":-9.710846,"eighty":-8.771001,"marketCap":807531900},{"date":"2026-04-10","current":-14.983685,"twenty":-12.570606,"median":-9.775997,"eighty":-8.798761,"marketCap":1031926357},{"date":"2026-04-17","current":-14.000462,"twenty":-13.015147,"median":-9.975459,"eighty":-8.828576,"marketCap":964211818},{"date":"2026-04-24","current":-13.514081,"twenty":-13.425068,"median":-10.075701,"eighty":-8.877926,"marketCap":930714732},{"date":"2026-05-01","current":-12.44718,"twenty":-13.370677,"median":-10.26642,"eighty":-8.898489,"marketCap":857237253},{"date":"2026-05-08","current":-11.767292,"twenty":-13.351187,"median":-10.76455,"eighty":-8.934568,"marketCap":810413370},{"date":"2026-05-15","current":-10.76944,"twenty":-13.300701,"median":-10.81684,"eighty":-8.966981,"marketCap":818337411},{"date":"2026-05-22","current":-11.162865,"twenty":-13.208546,"median":-10.76944,"eighty":-8.989273,"marketCap":848232660},{"date":"2026-05-29","current":-11.058584,"twenty":-13.135327,"median":-10.864241,"eighty":-9.002829,"marketCap":840308618},{"date":"2026-06-05","current":-9.807205,"twenty":-13.084182,"median":-10.80499,"eighty":-9.017037,"marketCap":745220116},{"date":"2026-06-12","current":-9.807205,"twenty":-13.030837,"median":-10.755219,"eighty":-9.036643,"marketCap":745220116},{"date":"2026-06-18","current":-9.788245,"twenty":-12.946112,"median":-10.53322,"eighty":-9.042258,"marketCap":743779381},{"date":"2026-06-26","current":-11.43779,"twenty":-12.867664,"median":-10.624868,"eighty":-9.042428,"marketCap":869123316},{"date":"2026-07-02","current":-6.07677,"twenty":-12.855112,"median":-10.547048,"eighty":-9.032928,"marketCap":461755529},{"date":"2026-07-10","current":-6.403835,"twenty":-12.813273,"median":-10.376014,"eighty":-8.958621,"marketCap":486608205},{"date":"2026-07-17","current":-5.550622,"twenty":-12.635456,"median":-10.177718,"eighty":-8.800817,"marketCap":421775136},{"date":"2026-07-24","current":-5.36576,"twenty":-12.598847,"median":-10.075701,"eighty":-8.689259,"marketCap":407727971},{"date":"2026-07-31","current":-5.37998,"twenty":-12.561192,"median":-10.06542,"eighty":-8.56425,"marketCap":408808522},{"date":"2026-08-07","current":-5.090694,"twenty":-12.489019,"median":-9.881902,"eighty":-8.43493,"marketCap":481925817},{"date":"2026-08-14","current":-5.393903,"twenty":-12.464961,"median":-9.807205,"eighty":-8.177768,"marketCap":510630029},{"date":"2026-08-21","current":-5.202222,"twenty":-12.450318,"median":-9.782121,"eighty":-7.430686,"marketCap":492483973}],"updateTime":1787507876686},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EVMN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659150197","title":"Analysts Are Bullish on Top NA Stocks: BitGo Holdings, Inc. Class A (BTGO), Evommune, Inc. (EVMN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659150197","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659150197?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:40","pubTimestamp":1786628434,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on BitGo Holdings, Inc. Class A (BTGO) and Evommune, Inc. (EVMN...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-bitgo-holdings-inc-class-a-btgo-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-bitgo-holdings-inc-class-a-btgo-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","BTGO","BK4127","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658931856","title":"Evercore ISI Keeps Their Buy Rating on Evommune, Inc. (EVMN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658931856","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658931856?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:45","pubTimestamp":1786365951,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Evommune, Inc. today and set a price target of $22.00. Clark-Gartner covers the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-keeps-their-buy-rating-on-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-keeps-their-buy-rating-on-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657646812","title":"RBC Adjusts PT on Evommune to $29 From $30, Maintains Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657646812","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657646812?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:46","pubTimestamp":1786106799,"startTime":"0","endTime":"0","summary":"Evommune (EVMN) has an average rating of buy and mean price target of $32.78, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657453676","title":"Evommune price target lowered to $29 from $30 at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2657453676","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657453676?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:21","pubTimestamp":1786105261,"startTime":"0","endTime":"0","summary":"RBC Capital lowered the firm’s price target on Evommune (EVMN) to $29 from $30 and keeps an Outperform rating on the shares. Despite the stock’s re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-price-target-lowered-to-29-from-30-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-price-target-lowered-to-29-from-30-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657066615","title":"Analysts Conflicted on These NA Names: Fiserv (FISV), Evommune, Inc. (EVMN) and Waystar Holding Corp. (WAY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657066615","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657066615?lang=en_us&edition=fundamental","pubTime":"2026-08-07 16:40","pubTimestamp":1786092008,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the NA sector with new ratings on Fiserv (FISV), Evommune, Inc. (EVMN) and Waystar Holding Corp. (WAY). Fis...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-na-names-fiserv-fisv-evommune-inc-evmn-and-waystar-holding-corp-way-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-na-names-fiserv-fisv-evommune-inc-evmn-and-waystar-holding-corp-way-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1923622291.USD","BK4227","LU1815336091.USD","BK4167","LU1169589451.USD","LU1046421795.USD","LU2125909916.SGD","NA","BK4141","LU0648000940.SGD","EVMN","LU0757428866.USD","LU1861217088.USD","WAY","LU1201861165.SGD","BK4588","LU1823568750.SGD","LU1201861249.SGD","LU0070302665.USD","LU0208291251.USD","LU0130103400.USD","LU0320765489.SGD","BK4139","LU0354030438.USD","LU0130102774.USD","FISV","LU1169590202.USD","FINX","LU0980610538.SGD","LU1861220207.SGD","LU2125909759.SGD","LU0648001328.SGD","LU0354030511.USD","BK4106","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657669650","title":"Evommune Posts Corporate Presentation Outlining Phase 2 Inflammation-Drug Pipeline Focusing on Evo756, Evo301","url":"https://stock-news.laohu8.com/highlight/detail?id=2657669650","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657669650?lang=en_us&edition=fundamental","pubTime":"2026-08-07 06:11","pubTimestamp":1786054289,"startTime":"0","endTime":"0","summary":"Evommune posts corporate presentation outlining Phase 2 inflammation-drug pipeline focusing on EVO756, EVO301Evommune outlined two Phase 2 programs in chronic inflammatory diseases, led by EVO756 in a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLcdShYX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650670","title":"Evommune Q2 FY26 Net Loss Widens to $32.25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650670","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650670?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:17","pubTimestamp":1786047455,"startTime":"0","endTime":"0","summary":"Evommune Q2 FY26 net loss widens to $32.25 millionEvommune posted a Q2 net loss of USD 32.25 million, widening from USD 13.57 million a year earlier.R&D expense rose 34.49% to USD 26.41 million, while","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL1n2hZk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872837","title":"Evommune Starts Phase 2b Trial of Evo756 for Migraine Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872837","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872837?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:01","pubTimestamp":1785412874,"startTime":"0","endTime":"0","summary":"Evommune starts Phase 2b trial of EVO756 for migraine preventionEvommune launched a Phase 2b trial of oral MRGPRX2 inhibitor EVO756 for migraine prevention, dosing the first patient.Top-line results h","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDLrzbqn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655874090","title":"Evommune - Top-Line Data from Phase 2B Trial Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2655874090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655874090?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA8LHQNZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655387476","title":"Evommune Initiates Phase 2B Clinical Trial of Mrgprx2 Inhibitor Evo756 in Migraine Prophylaxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2655387476","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655387476?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA8LHQNZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650158610","title":"Evommune CFO Kyle Carver Acquires 1,000 Common Shares for $13,260","url":"https://stock-news.laohu8.com/highlight/detail?id=2650158610","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650158610?lang=en_us&edition=fundamental","pubTime":"2026-07-11 08:00","pubTimestamp":1783728046,"startTime":"0","endTime":"0","summary":"Evommune CFO Kyle Carver acquires 1,000 common shares for $13,260Evommune CFO Kyle Carver bought 1,000 common shares at USD 13.26.Direct holdings rose to 60,335 shares.Disclaimer:This news brief was c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260711:nNDL4JpcFl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Evommune CFO Kyle Carver Acquires 1,000 Common Shares for $13,260","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650110138","title":"Independent Director of Evommune Arthur Kirsch Buys More Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2650110138","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650110138?lang=en_us&edition=fundamental","pubTime":"2026-07-10 19:35","pubTimestamp":1783683354,"startTime":"0","endTime":"0","summary":"Investors who take an interest in Evommune, Inc. ( NYSE:EVMN ) should definitely note that the Independent Director...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-evmn/evommune/news/independent-director-of-evommune-arthur-kirsch-buys-more-sto","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-evmn/evommune/news/independent-director-of-evommune-arthur-kirsch-buys-more-sto","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650691432","title":"Evommune Director Arthur S. Kirsch Reports Purchase of $133,000 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2650691432","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650691432?lang=en_us&edition=fundamental","pubTime":"2026-07-09 08:00","pubTimestamp":1783555257,"startTime":"0","endTime":"0","summary":"Evommune director Arthur S. Kirsch reports purchase of $133,000 in common sharesEvommune director Arthur S. Kirsch bought 10,000 common shares at USD 13.3, raising beneficial ownership to 10,000 share","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDL4D2tWD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Evommune Director Arthur S. Kirsch Reports Purchase of $133,000 in Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649675371","title":"Evommune Publishes Corporate Deck Outlining Chronic Inflammation Drug Pipeline, Led by Evo756 and Evo301 Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2649675371","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649675371?lang=en_us&edition=fundamental","pubTime":"2026-07-07 01:32","pubTimestamp":1783359122,"startTime":"0","endTime":"0","summary":"Evommune publishes corporate deck outlining chronic inflammation drug pipeline, led by EVO756 and EVO301 programsEvommune highlighted two Phase 2 inflammation assets, led by oral MRGPRX2 antagonist EV","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL9Rh4JP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649645924","title":"Stifel Nicolaus Sticks to Their Buy Rating for Evommune, Inc. (EVMN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649645924","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649645924?lang=en_us&edition=fundamental","pubTime":"2026-07-06 13:55","pubTimestamp":1783317335,"startTime":"0","endTime":"0","summary":"In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Evommune, Inc., with a price target of $54.00. Thomps...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-their-buy-rating-for-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-their-buy-rating-for-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","SF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648654790","title":"Evommune’s EVO756 Migraine Trial: What Investors Should Know About This New Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2648654790","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648654790?lang=en_us&edition=fundamental","pubTime":"2026-07-02 00:31","pubTimestamp":1782923460,"startTime":"0","endTime":"0","summary":"Evommune, Inc. ($EVMN) announced an update on their ongoing clinical study. The Phase 2 study “A Randomized, Double-Blind, Placebo Controlled Study...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evommunes-evo756-migraine-trial-what-investors-should-know-about-this-new-phase-2-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evommunes-evo756-migraine-trial-what-investors-should-know-about-this-new-phase-2-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","BK4139","ISBC","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648547135","title":"Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2648547135","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648547135?lang=en_us&edition=fundamental","pubTime":"2026-07-02 00:30","pubTimestamp":1782923439,"startTime":"0","endTime":"0","summary":"Evommune, Inc. ($EVMN) announced an update on their ongoing clinical study. Evommune, Inc. has completed a Phase 2b trial of EVO756 in adults with ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evommunes-evo756-trial-completion-signals-key-milestone-in-chronic-urticaria-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evommunes-evo756-trial-completion-signals-key-milestone-in-chronic-urticaria-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647591635","title":"Evommune is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2647591635","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647591635?lang=en_us&edition=fundamental","pubTime":"2026-06-30 21:06","pubTimestamp":1782824760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVMN/analyst-ratings(END) Dow Jones NewswiresJune 30, 2026 09:06 ET","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647300545","title":"HC Wainwright Downgrades Evommune to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2647300545","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647300545?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:14","pubTimestamp":1782818047,"startTime":"0","endTime":"0","summary":"HC Wainwright Downgrades Evommune to Neutral From Buy","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647533196","title":"U.S. Research Roundup- Comcast, Honeywell Aerospace, Qualys","url":"https://stock-news.laohu8.com/highlight/detail?id=2647533196","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647533196?lang=en_us&edition=fundamental","pubTime":"2026-06-30 15:51","pubTimestamp":1782805890,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Comcast, Honeywell Aerospace, QualysJune 30 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Comcast","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nL8N4320EF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GOOX","BKNG","ASTH","AMDS","BROS","CMCSA","GOOY","CNR","GOOGL","HONA","HON","DOW","CNXC","AMDL","BKU","AMDG","EXPE","FUL","GSX","FOXF","AMD","EOG","EVRG","HWKN","AVAV","AMDU","EVMN","HRMY","BAC","FCBC","AIR","AMDY","FBIN","ABVX","GNRC","GOU","AAL","AMDD","TECH","CELH","DAL","CHTR","EVH","AMYY","CE","DIS","GOOP","GOOW","AA","AADX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":84,"code":"91000000","status":"200"}]}}